BRIEF-GSK says asthma drug Nucala (Mepolizumab) meets primary endpoints

GlaxoSmithKline Plc:

* Phase IIIB Musca study successfully met all its primary and secondary endpoints

* Patients treated with Nucala (Mepolizumab) achieved clinically and statistically significant improvements in quality of life and lung function versus placebo

* St. Georges respiratory questionnaire improved by 7.7 units from baseline versus. Placebo (p=0.001)

* Lung function (first secondary endpoint), as measured by pre-bronchodilator fev1, increased by 120ml (p=0.001) more than in placebo patients

* Asthma control showed a significant improvement versus. Placebo in Mepolizumab treatment group by 0.40 units (p<0.001)

* Safety profile of Mepolizumab in Musca study was consistent with product label for Nucala Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)